Login
$BIAF
$1.98 -$0.02 (1.0%) After hours

$BIAF 8-K SEC Filings

Filed On Filing
06 Nov 2026 8-K: Results of Operations and Financial Condition

CyPath® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases 79% year-to-date

29 Oct 2026 8-K: Other Events

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month

15 Oct 2026 8-K: Other Events

Presentation to address current challenges in pulmonary nodule management and to discuss preliminary research data from the ongoing development of a new, investigational test for asthma and COPD

13 Oct 2026 8-K: Other Events

bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

09 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of approximately $4,000,000 of registered and unregistered sec...

08 Oct 2026 8-K: Other Events

bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm

06 Oct 2026 8-K: Other Events

SAN ANTONIO, TEXAS — October 6, 2026 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that...

30 Sep 2026 8-K: Other Events

bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL

22 Sep 2026 8-K: Other Events

bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference

17 Sep 2026 8-K: Other Events

bioAffinity Technologies Announces Grant of Hong Kong Patent for Company’s CyPath® Lung Noninvasive Lung Cancer Diagnostic

11 Sep 2026 8-K: Regulation FD Disclosure

bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time in presentations about the Company’s operations a...

09 Sep 2026 8-K: Other Events

SAN ANTONIO, TX — September 9, 2026 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that ...

03 Sep 2026 8-K: Other Events

SAN ANTONIO, Texas – September 3, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced tha...

01 Sep 2026 8-K: Other Events

More than 680,000 Americans living with a history of lung cancer represent a significant population requiring ongoing surveillance

20 Aug 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

SAN ANTONIO, TX – August 20, 2026 – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-...

18 Aug 2026 8-K: Other Events

New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide

14 Aug 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into effective as of August 12, 2026, between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signatur...

07 Aug 2026 8-K: Results of Operations and Financial Condition

Pipeline expands to include development of precision diagnostics for asthma and COPD and dermally delivered skin cancer therapeutics

31 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 30, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) received written notice (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying t...

27 Jul 2026 8-K: Other Events

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support